Real world outcomes with Elranatamab
@AJPortuguese
#mmsm
#Outcomedata
#ASH2025
@fredhutch
@RahulBanerjeeMD
@ASH_hematology
Included patients that were excluded from MagnetisMM-3 like frail,
ECOG >2, prior BCMA exposure
Comparison to MagnetisMM-3
⭕️Worse baseline performance status (ECOG ≥2: 35% vs 5.7%)
⭕️Inferior survival outcomes in real-world:
🩸OS: 14.6 months (vs 24.6 months in trial)
🩸PFS: 4.3 months (vs 17.2 months)
⭕️Predictors of Outcome
🩸Baseline Hemoglobin (Hgb) and LDH strong predictors:
🩸Low Hgb <10 high LDH>300: Worse PFS